Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free HEMO Stock Alerts

Hemogenyx Pharmaceuticals (HEMO) Competitors

Hemogenyx Pharmaceuticals logo
GBX 679.50 -5.50 (-0.80%)
As of 05/15/2026 12:25 PM Eastern
Compare

HEMO vs. CIR, TILS, VSN, MPH, and BVXP

Should you buy Hemogenyx Pharmaceuticals stock or one of its competitors? MarketBeat compares Hemogenyx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hemogenyx Pharmaceuticals include Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), Mereo BioPharma Group plc (MPH.L) (MPH), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry.

How does Hemogenyx Pharmaceuticals compare to Circassia Group?

Circassia Group (LON:CIR) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Circassia Group's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Circassia Group Neutral
Hemogenyx Pharmaceuticals Neutral

Circassia Group's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Circassia GroupN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

0.2% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Circassia Group has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Circassia Group£27.90M0.00N/A£0.01N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

Summary

Circassia Group beats Hemogenyx Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Tiziana Life Sciences?

Hemogenyx Pharmaceuticals (LON:HEMO) and Tiziana Life Sciences (LON:TILS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 1 mentions for Tiziana Life Sciences and 0 mentions for Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Tiziana Life Sciences'average media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Tiziana Life Sciences Neutral

Tiziana Life Sciences' return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Tiziana Life Sciences N/A N/A N/A

0.2% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Tiziana Life Sciences has lower revenue, but higher earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A

Summary

Tiziana Life Sciences beats Hemogenyx Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Verseon?

Hemogenyx Pharmaceuticals (LON:HEMO) and Verseon (LON:VSN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Verseon Neutral

Verseon's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Verseon N/A N/A N/A

0.2% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
VerseonN/AN/AN/A-£14.30N/A

Summary

Hemogenyx Pharmaceuticals and Verseon tied by winning 3 of the 6 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma Group plc (MPH.L)N/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

0.2% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Mereo BioPharma Group plc (MPH.L) Neutral
Hemogenyx Pharmaceuticals Neutral

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

Summary

Mereo BioPharma Group plc (MPH.L) beats Hemogenyx Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Bioventix?

Bioventix (LON:BVXP) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Bioventix has a beta of 0.484, meaning that its stock price is 52% less volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.544, meaning that its stock price is 54% more volatile than the broader market.

Bioventix has a net margin of 59.30% compared to Hemogenyx Pharmaceuticals' net margin of 0.00%. Bioventix's return on equity of 65.83% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix59.30% 65.83% 54.07%
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

In the previous week, Bioventix had 1 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 1 mentions for Bioventix and 0 mentions for Hemogenyx Pharmaceuticals. Bioventix's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Bioventix Neutral
Hemogenyx Pharmaceuticals Neutral

21.1% of Bioventix shares are held by institutional investors. Comparatively, 0.2% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 6.2% of Bioventix shares are held by insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Bioventix has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.54M7.08£8.12M£140.5212.10
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

Summary

Bioventix beats Hemogenyx Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

Get Hemogenyx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HEMO vs. The Competition

Export
MetricHemogenyx PharmaceuticalsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£43.66M£467.15M£6.33B£2.74B
Dividend YieldN/A3.86%2.80%6.07%
P/E Ratio-3.983.8820.29365.91
Price / SalesN/A7,763.50548.2688,016.94
Price / Cash2.0513.1343.0427.89
Price / Book2,758.1784.219.837.74
Net Income-£6.89K-£96.07M£3.56B£5.89B
7 Day Performance-2.79%0.89%0.25%0.25%
1 Month Performance-25.82%0.44%-1.30%1.56%
1 Year Performance278.55%68.68%33.61%85.82%

Hemogenyx Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 679.50
-0.8%		N/A+280.7%£43.66MN/AN/A14
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:HEMO) was last updated on 5/16/2026 by MarketBeat.com Staff.
From Our Partners
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Secret behind near perfectly timed stock trades…?
After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...
Traders Agency | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
The gold strategy that works whether prices rise or fall
Former $900 million hedge fund manager Larry Benedict has developed a strategy he calls Gold Skimming - a way ...
Brownstone Research | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
The NASTY TRUTH about the SpaceX IPO
In nearly every major IPO, roughly 95% of the gains are captured before retail investors can place a trade. It...
The Oxford Club | Sponsoredtc pixel